Alkermes Plc
NASDAQ:ALKS
Intrinsic Value
Alkermes Plc is a global biopharmaceutical company. [ Read More ]
The intrinsic value of one ALKS stock under the Base Case scenario is 31.77 USD. Compared to the current market price of 23.85 USD, Alkermes Plc is Undervalued by 25%.
Valuation Backtest
Alkermes Plc
Run backtest to discover the historical profit from buying and selling ALKS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Alkermes Plc
Current Assets | 1.5B |
Cash & Short-Term Investments | 1.1B |
Receivables | 333.2m |
Other Current Assets | 22.9m |
Non-Current Assets | 650.7m |
Long-Term Investments | 39.9m |
PP&E | 318.4m |
Intangibles | 85m |
Other Non-Current Assets | 207.4m |
Current Liabilities | 520.2m |
Accounts Payable | 65.6m |
Accrued Liabilities | 444.3m |
Other Current Liabilities | 10.3m |
Non-Current Liabilities | 413.3m |
Long-Term Debt | 287.7m |
Other Non-Current Liabilities | 125.6m |
Earnings Waterfall
Alkermes Plc
Revenue
|
1.7B
USD
|
Cost of Revenue
|
-253m
USD
|
Gross Profit
|
1.4B
USD
|
Operating Expenses
|
-990.2m
USD
|
Operating Income
|
420.1m
USD
|
Other Expenses
|
-64.4m
USD
|
Net Income
|
355.8m
USD
|
Free Cash Flow Analysis
Alkermes Plc
What is Free Cash Flow?
ALKS Profitability Score
Profitability Due Diligence
Alkermes Plc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
Alkermes Plc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
ALKS Solvency Score
Solvency Due Diligence
Alkermes Plc's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Score
Alkermes Plc's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALKS Price Targets Summary
Alkermes Plc
According to Wall Street analysts, the average 1-year price target for ALKS is 36.44 USD with a low forecast of 23.23 USD and a high forecast of 52.5 USD.
Ownership
ALKS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ALKS Price
Alkermes Plc
Average Annual Return | -2.99% |
Standard Deviation of Annual Returns | 27.21% |
Max Drawdown | -62% |
Market Capitalization | 4B USD |
Shares Outstanding | 170 138 000 |
Percentage of Shares Shorted | 9.79% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Alkermes Plc is a global biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 2,211 full-time employees. The firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The company has a portfolio of commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. The firm's products include ALKERMES, ARISTADA, ARISTADA INITIO, LinkeRx, LYBALVI, NanoCrystal and VIVITROL. Its other trademark includes INVEGA SUSTENNA, INVEGA TRINZA, TREVICTA, XEPLION, and RISPERDAL CONSTA, KEYTRUDA and VUMERITY. The firm's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
Contact
IPO
Employees
Officers
The intrinsic value of one ALKS stock under the Base Case scenario is 31.77 USD.
Compared to the current market price of 23.85 USD, Alkermes Plc is Undervalued by 25%.